All sponsors

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. $1093.HK

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS9
PHASE 3 / 2-35
RECRUITING5
READOUTS ≤12 MONTHS3
Open CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. on the live radar map → 📅 $1093.HK readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Mitoxantrone hydrochloride liposome injection
NCT05717764
P3Not yet recruitingRecurrent Metastatic Nasopharyngeal Carcinoma5002026-09
SYH2062
NCT07940075
P2RecruitingMild to Moderate Primary Hypertension3602027-01-31
SYH2070
NCT07695597
P2RecruitingMixed Hyperlipidemia2402027-04-30
SYH2070 injection dose1
NCT07591298
P2RecruitingDiagnosed With HoFH182027-09-16
NCT07421284
NCT07421284
P3Not yet recruitingNon-familial Hypercholesterolemia and Mixed Hyperlipidemia9002027-12-31
SYH2053 injection
NCT07421297
P3RecruitingNon-familial Hypercholesterolemia and Mixed Hyperlipidemia7602027-12-31
SYH2053 Injection
NCT07465263
P3RecruitingHeterozygous Familial Hypercholesterolemia (HeFH)1352028-02-28
SYH2068 Dose 1
NCT07640217
P2Not yet recruitingAdult Participants With Elevated Lipoprotein(a)1202028-03-30
Aprocitentan tablets(SYH9108)
NCT07635914
P3Not yet recruitingResistant Hypertension3822029-12-28